A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
Amgen
Stanford University
UNC Lineberger Comprehensive Cancer Center
University Health Network, Toronto
Abramson Cancer Center at Penn Medicine
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Massachusetts Eye and Ear Infirmary
Amgen
Peking University People's Hospital
Greenwich LifeSciences, Inc.